Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Aronex Pharma (ARNX) -- Ignore unavailable to you. Want to Upgrade?

To: Vendit™ who wrote (197)	12/8/1998 2:18:00 PM
From: Robert Floyd	Read Replies (1) \| Respond to of 320

European Union (EU) My mistake though, it was only Spain: ARONEX PHARMACEUTICALS SEEKS EUROPEAN MARKETING APPROVAL IN SPAIN FOR NYOTRAN™ ANTIFUNGAL PRODUCT -- Nyotran™ Advances Towards European Commercialization -- -------------------------------------------------------------------------------- The Woodlands, Texas, December 19, 1997 -- Aronex Pharmaceuticals, Inc. (Nasdaq/National Market: ARNX), a biopharmaceutical company focused on proprietary medicines to treat cancer and life-threatening infections, announced today that it has filed a Marketing Authorization Application (MAA) in Spain seeking approval for Nyotran™ for the treatment of systemic fungal infections. This filing was made in cooperation with Grupo Ferrer Internacional, S.A., the Company's corporate partner for the commercialization and marketing of Nyotran in Spain and Portugal. Geoffrey F. Cox, Ph.D., Chairman and CEO of Aronex Pharmaceuticals stated: "Aronex Pharmaceuticals formed its collaboration with Ferrer in May of this year, and announced at that time its intention to file for Spanish approval in 1997. We are pleased to have fulfilled this objective according to plan. In line with our strategy for the development and commercialization of Nyotran, we are filing the MAA in Spain initially, to be followed by additional filings in other European countries and the U.S." Nyotran is a lipid-based, intravenous formulation of nystatin, an established, widely-used topical antifungal agent. Aronex Pharmaceuticals believes the drug displays a broader spectrum of activity and significantly less toxicity than other products available to the physician. Systemic fungal infections continue to be a major health care problem, with more than 300,000 infections diagnosed worldwide on an annual basis. Aronex Pharmaceuticals, Inc. is a leading biopharmaceutical company engaged in the identification and development of proprietary innovative medicines to treat cancer and life-threatening infectious diseases. Aronex currently has four products (Nyotran™, ATRAGEN™, Annamycin and Zintevir™) in various stages of ongoing clinical development and a number of products in preclinical development. Any statements which are not historical facts contained in this release are forward looking statements that involve risks and uncertainties, including but not limited to those relating to the Company's early stage of development, future capital needs, uncertainties related to clinical trial results, governmental regulations, no assurance of regulatory approval of products, uncertainty of protection for patents and proprietary technology, manufacturing uncertainties, reliance on third-party suppliers, lack of sales and marketing experience, risks associated with collaborative arrangements, competition and technological change, no assurance of adequate third-party reimbursement, potential product liability, availability of insurance and other risks identified in the Company's Securities and Exchange Commission filings